source
- Merck and Moderna report positive late-stage melanoma vaccine results, adding to 2026 cancer breakthrough yearMerck and Moderna announced that their personalized mRNA neoantigen vaccine achieved positive outcomes in a late-stage trial for melanoma patients. The data suggest the vaccine can stimulate an imm…
- Eli Lilly teams with Amplitude on taRNA vaccine platform as Otsuka ends psychedelic trialEli Lilly announced a collaboration with Amplitude Therapeutics to co‑develop vaccine candidates using a trans‑amplifying RNA (taRNA) platform. The taRNA approach aims to boost antigen expression…